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INTRODUCTION
It is now clearly accepted that clonal expansion and tumor
growth result not only from the acceleration of intrinsic pro-
liferation, but also from escape from apoptotic cell death. The
Fas receptor (APO-1 or CD95) and its ligand (FasL) play a
key role in the initiation of one apoptotic pathway (1). Alter-
ations in this pathway within tumor cells can result in escape
from apoptosis and immune surveillance. In malignant cells,
their reduced capability to undergo apoptosis in response to
some physiological stimuli results in a significant survival
advantage and may contribute to tumorigenesis (2, 3). A pre-
vious study reported that loss of Fas expression is an integral
part of the process of lung tumorigenesis, by allowing lung
tumor cells to escape attack by activated cytotoxic T cells
which are frequently present in non-small cell lung carcino-
mas (NSCLCs) (4). Fas ligand (FasL) expression in lung car-
cinomas has also been proposed to play a role in allowing
escape from immune surveillance via a mechanism of periph-
eral deletion of tumor-reactive T cell clones (5).
Therefore, the analysis of Fas and FasL protein expression
is essential for the evaluation of potential pathologic alterations
of apoptotic pathways in human NSCLCs, and in fact, the Fas
pathway alterations have been reported in a variety of solid
human tumors including lung carcinomas (6-11). The expres-
sion of Fas in tumor samples, however, does not necessarily
predict susceptibility to death, because Fas-mediated apop-
tosis can be blocked by the lack of p53-mediated activation
of Fas/FasL system (12). Recent evidence suggests an intrigu-
ing link between p53 and Fas pathway. Munsch et al. reported
that intron 1 and promoter of the human Fas death receptor
gene contain a p53-responsive element, which is specifically
bound only by wild-type p53 (13). Also, mutated p53 has so
far been identified as being involved in transcriptional down-
regulation of Fas in malignant cells (14). 
Initiation of apoptosis occurs principally by signals from
two distinct but convergent pathways, the extrinsic or Fas
receptor-mediated pathway and the intrinsic, or mitochondrial
pathway (15). Bcl-2 normally resides in mitochondrial mem-
branes and the cytoplasm, whose overexpression is another
potential mechanism for apoptotic resistance. However, its
role in the apoptotic resistance and the relationship with Fas
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Tissue Microarray Analysis of Fas and FasL Expressions in Human
Non-small Cell Lung Carcinomas; with Reference to the p53 and 
bcl-2 Overexpressions
Lack of surface Fas expression is a main route for apoptotic resistance which is con-
sidered an important mechanism of tumorigenesis and tumor progression. Fas and
FasL expressions in 110 non-small cell lung carcinomas (NSCLCs) were investi-
gated to evaluate their roles in pulmonary carcinogenesis and to examine the clini-
copathologic significance of Fas expression with its relationship with p53 and bcl-2
overexpressions. Immunohistochemical analysis using tissue microarray demon-
strated that a large proportion of NSCLC patients (60%) showed lack of membra-
nous Fas expression. The Fas-negative cases revealed the significantly lower sur-
vival rate than Fas-positive ones. Also, the loss of Fas receptor expression was
found more frequently in advanced stage and higher nodal status. FasL protein was
increased in most NSCLCs (89%) compared to normal lungs. p53 and bcl-2 over-
expressions showed no association with Fas expression. Conclusively, reduced
membranous Fas expression as a mechanism of apoptotic resistance is considered
to play an important part of the pulmonary carcinogenesis, which may predict poor
survival and have a bad prognostic influence. Increased FasL expression is thought
to be a basis for the immune evasion in NSCLCs. The rare bcl-2 overexpression
suggests that this anti-apoptotic protein is unlikely to play a role in the apoptotic resis-
tance of NSCLCs.
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expression has not yet been studied well (10).
Herein, I report results of the first study in which tissue
microarrays (TMAs) were used for large-scale investigation
of the biologic and prognostic value of Fas and FasL proteins
in 110 NSCLC tumors. Also, I evaluate the relationships of
p53 and bcl-2 overexpressions with the altered Fas expression
in the respect of apoptotic resistance.
MATERIALS AND METHODS
Patients and tissue samples
A total of 110 consecutive patients with completely resect-
ed stage I-III NSCLCs from 1994 to 2002 at Dankook Uni-
versity Hospital (DKUH) was retrospectively evaluated. Patho-
logic tumor staging was performed according to the tumor-
node-metastasis (TNM) Classification of AJCC staging sys-
tem. All patients had complete medical records and had a
median follow-up period of 37 months (range, 15 days to 105
months). The demographic and clinical data such as age, sex,
smoking history, and TNM status were collected from the
hospital records. Death from lung cancer was the terminal
event for survival calculations. Formalin-fixed and paraffin-
embedded tumor specimens were obtained from the depart-
ment of pathology at DKUH and all hematoxylin-eosin stained
slides of the tumor samples were reviewed by a pathologist.
They were histologically subtyped and graded according to
the World Health Organization (WHO) diagnostic criteria
for lung carcinomas. There were 58 squamous carcinomas, 32
adenocarcinomas, 3 adenosquamous carcinomas (ASCs), 3
bronchioloalveolar carcinomas (BACs), 6 large cell carcinomas,
and 8 pleomorphic carcinomas.
Tissue microarray (TMA) construction 
Briefly, the most representative tumor and normal areas
were carefully selected in pairs and marked as a circle on the
H&E slides in a diameter of 2 mm. The corresponding areas
of the donor paraffin blocks were punched by the trephine
needle with the hole size of 2 mm. These 2 mm-sized tissue
cores were transferred and embedded into the recipient block
with 60 empty 2 mm-sized holes. All study specimens were
sampled with both tumor and normal regions from each donor
block. Multiple 4  m-thick sections were cut with a micro-
tome and transferred to poly-L-lysine-coated slides.
Immunohistochemical staining and its semiquantitative
analysis
The standard avidin-biotin-peroxidase complex method
was used for the immunohistochemical examination with
mouse monoclonal antibodies against Fas (GM30, Novocastra,
Newcastle upon Tyne, U.K.), FasL (clone 33, Transduction
Lab., Lexington, KY, U.S.A.), p53 (DO7, Novocastra), and
bcl-2 (clone 124, DAKO, Goldstrup, Denmark).
The microarrayed tissue sections were deparaffinized with
standard xylene and hydrated through graded ethyl alcohols
into water. The sections were microwaved in 10 mM citrate
buffer at 90℃ for 10 min, and treated with 3% H2O2-PBS
solution to reduce endogenous peroxidase activity. Then,
they were incubated with normal bovine serum to reduce
nonspecific antibody binding and were subsequently subject-
ed to the primary antibody reactions. The primary antibodies
for Fas, FasL, p53, and bcl-2 were reacted with the sections
at room temperature for one hour at the dilution of 1:40, 1:
100, 1:50, and 1:50, respectively. Detection of the immuno-
reactive staining was carried out by avidin-biotin-peroxidase
complex method using the LSAB kit (DAKO). The sections
were subjected to a color reaction with 3,3′ -diaminobenzidine
tetrahydrochloride containing 3% H2O2 in Tris buffer and
were lightly counterstained with Mayer’s hematoxylin. A neg-
ative control was incubated without the primary antibodies.
Positive or negative (or reduced) immunoreactivity for Fas
was defined by the following criteria; 1) the tumors were judged
to be Fas-positive when at least 5% of the tumor cells were
stained membranous only or mixed membranous and cyto-
plasmic; 2) they were Fas-negative (or reduced) when less than
5% of the tumor cells were stained membranous or when any
proportions of the tumor cells were stained cytoplasmic only.
FasL expression was evaluated according to the criteria of
Viard-Leveugle et al. (4), which was found in the cytoplasms
along the cell borders. The tumors were defined as increased
FasL expression, when the expression score is more than 100
for them. The FasL expression score is defined as percentage
of stained cells (0-100%)×staining intensity (0-3), which is
equal to 100 (area 100%×staining intensity 1) for normal
bronchial epithelial cells. The cases were considered positive
for p53 overexpression, when at least 50% of tumor cells
showed distinct nuclear immunopositivity because high p53
expression would be expected if p53 mutations existed (16).
The tumors were defined as bcl-2 overexpression when the
cytoplasmic immunopositivity was found in more than 10%
of tumor cells (17).
Statistical analysis
The chi-square test and the unpaired Student t-test were
used to examine the association between Fas expression and
various clinicopathologic parameters. The relationships of Fas
expression with p53 and bcl-2 overexpressions were analyzed
by chi-square and Fisher’s exact tests, respectively (SPSS 12.0K
for Windows, 2004). The survival period was calculated as
the time from the date of surgery to the date of death or last
follow-up. Postoperative survival curves were constructed
using the Kaplan-Meier method and then compared by the
log rank test. A p value less than 0.05 was defined as statis-
tically significant.772 N.-H. Myong
RESULTS
Clinicopathologic data and its relationship with Fas expres-
sion
The data were summarized in Table 1. The 110 NSCLC
patients consisted of 85 men and 25 women, with median
ages of 61 and 60 yr, respectively. Overall, the median age
at diagnosis was 60.4 yr. The pathological staging revealed
41 cases of stage 1, 30 of stage 2, and 39 of stage 3. Patho-
logical T stages were pT1 in 21 cases, pT2 in 60, pT3 in 24,
and pT4 in 5. Pathological N stages were pN0 in 51 cases,
pN1 in 28, pN2 in 31. Of 110 NSCLCs, only 90 cases of
squamous carcinoma and adenocarcinoma were histologically
graded as 14 cases of grade 1 (well differentiated), 54 of grade
2 (moderately differentiated), and 22 of grade 3 (poorly dif-
ferentiated). Overall, 66 (60%) of 110 cases showed negative
immunostaining for membranous Fas protein expression.
The negative immunoreactivity for Fas protein was found
more frequently in the advanced stage (stage 3) than in ear-
lier ones (stage 1-2) (p=0.023). Also, the membranous Fas
expression tended to be reduced more significantly in higher
(pN2) than in lower nodal status (pN0-1) (p=0.057). Other
clinocopathologic variables such as age, sex, smoking history,
tumor size (pT), and histologic grade and subtypes were not
significantly associated with the Fas expression. Bronchiolo-
alveolar carcinoma (BACs), which are thought to be a well-
differentiated form of adenocarcinoma, showed the highest
rate of membranous Fas ex- pression (100%) among all histo-
logic types, while ordinary adenocarcinomas expressed mem-
branous Fas positivity in only 37% of the cases. 
Relationship of Fas expression with survival
Patients with Fas-negative NSCLCs exhibit significantly
shorter survival times than did patients with Fas-positive
carcinomas, when their survival data were analyzed by Kaplan-
Meier method and then log-rank test (Fig. 1). The median
survival time of patients with Fas-negative tumors was 32
months, while that of patients with Fas-positive tumors was
67 months. The difference was statistically significant (p=
0.019). Additionally, the survival curves according to the
pathologic staging and lymph nodal status showed the sta-
tistically significant difference in survival rate between the
lower (stage 1-2) and higher (stage 3) stages (p=0.019), but
not between pN (0-1) and pN (2-3) (p=0.131) (data not
shown).
The immunohistochemical expressions of Fas, FasL, p53,
and bcl-2 proteins in normal lung and tumor tissues
110 microarrayed normal lung tissues revealed the distinct
membranous staining for Fas in bronchial and bronchiolar
epithelia, reactive lymphocytes, and histiocytes (Fig. 2), whereas
the alveolar lining cells were not stained. Most of the paired
Clinicopathologic
features
No. of
cases
p
value
Fas immunoreactivity
Negative 
(%)
Positive
(%)
Age
Age <60 yr 50 28 (56) 22 (44) 0.434
Age ≥60 yr 60 38 (63) 22 (37)
Mean age (±S.D.) 110 60.6±9.2 60.1±7.5 0.770
Sex
Male 85 53 (62) 32 (38) 0.199
Female 25 12 (48) 13 (52)
Smoking history
Smokers 85 54 (64) 31 (36) 0.164
Non-smokers 25 12 (48) 13 (52)
Stage
1-2 71 37 (52) 34 (48) 0.023
3 39 29 (74) 10 (26)
pT
1-2 81 45 (56) 36 (44) 0.112
3-4 29 21 (72) 8 (28)
pN
0-1 79 43 (54) 36 (46) 0.057
2-3 31 23 (74) 8 (26)
Grade
1-2 68 44 (65) 24 (35) 0.109
3 22 10 (45) 12 (55)
Histologic type
Squamous ca. 58 34 (59) 24 (41) 0.719*
Adenoca. 32 20 (63) 12 (37)
ASC 3 2 (67) 1 (33)
BAC 3 0 (0) 3 (100)
Large cell ca. 6 5 (83) 1 (17)
Pleomorphic ca. 8 5 (63) 3 (37)
Table 1. Correlation between Fas expression and clinicopatho-
logic features in 110 non-small cell lung carcinomas
S.D., standard deviation; ca., carcinoma; ASC, adenosquamous carci-
noma; BAC, bronchioloalveolar carcinoma; p value *between squamous
carcinoma and adenocarcinoma.
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Fig. 1. The Kaplan-Meier survival curves according to Fas immuno-
staining for 110 NSCLC patients. Significant difference in survival
times was observed between Fas-positive and Fas-negative cases
(log rank test p=0.019).
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NSCLC tumor samples (60%) showed a remarkable reduc-
tion of the membranous expression for Fas protein (Fig. 3A),
while there were some tumors showing strong immunoposi-
tivity for surface Fas protein (Fig. 3B). Of 66 Fas-negative
cases, 38 tumors (58%) showed complete loss of surface Fas
expression. On the other hand, expression of FasL protein was
found to be increased in the cytoplasms along the cell borders
in most NSCLCs (98 cases, 89%), when the threshold value
was chosen as the score 100 for normal bronchial epithelial
cells (Fig. 4A). The percentage of FasL-positive cells ranged
from 0% to 100% in each tumor, with the average rate of
Fig. 2. Normal lung tissue reveal distinct membranous immunore-
activity for Fas protein in bronchiolar epithelia and reactive lym-
phocytes (×400).
Fig. 3. Immunohistochemical finding of Fas-negative (A) and Fas-
positive (B) squamous carcinomas (×400). The Fas-negative car-
cinoma (A) shows complete loss of surface Fas expression com-
pared to Fas-expressing reactive lymphocytes. The Fas-positive
carcinoma (B) reveals diffuse membranous immunopositivity simi-
lar to that of adjacent lymphocytes.
A B
Fig. 5. Diffuse and strong immunopositivity for nuclear p53 protein
in a case of squamous carcinoma (×400).
Fig. 4. A case of well-differentiated adenocarcinoma (B) showing
increased FasL expression compared to the normal bronchial
epithelia (A). FasL protein is immunohistochemically expressed
in the cytoplasms along the cell borders (×400).
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about 92%, and 79 tumors (80%) showed immunoreactivity
of 100% with at least moderate intensity (Fig. 4B). In nor-
mal and neoplastic lung tissues, expression of FasL protein
was mainly found in the cytoplasms along the cell membrane
borders of bronchial epithelia. In addition, reactive lympho-
cytes and histiocytes were also stained for FasL. p53 immunos-
taining revealed the distinct nuclear expression in tumors, in
comparison to no immunoreactivity in normal lung tissues
(Fig. 5). The cytoplasmic bcl-2 protein was expressed around
the nuclei of the tumor cells as well as normal lymphoid cells
(Fig. 6).
Association of Fas expression with p53 and bcl-2 overex-
pressions
The statistical analysis for the correlations between Fas ex-
pression and p53 or bcl-2 overexpression was shown in Table
2, 3. Of 109 NSCLCs, 59 cases (54%) showed p53 overex-
pression which is defined as distinct nuclear immunoreactivity
for p53 protein in the tumor cells over than 50%, but there
was no significant correlation between Fas expression and
overexpression of p53 protein which is known for a regulator
of Fas expression. The cytoplasmic bcl-2 protein was over-
expressed in 8 cases only (7.3%), and the bcl-2 overexpres-
sion, which is considered as a mechanism of apoptotic resis-
tance, was not correlated with the Fas expression, either. The
immunostaining results for p53 and bcl-2 overexpressions
are shown representatively in Fig. 5, 6.
DISCUSSION
The surface expression of Fas on a malignant target cell is
a prerequisite for a tumoricidal attack by immune effector
cells through Fas/FasL interactions (6). There is now broad
evidence demonstrating that malignant cells draw advantage
from aberrant loss of Fas and increased Fas-ligand expression,
as compared to their normal counterparts (18). In order to
eventually determine a pathogenetic and prognostic role of
the Fas-FasL pathway in lung cancer, their expressions in a
well-defined group of 110 NSCLCs were investigated by a
high-throughput study using TMA, with a reference to the
relationship with overexpression of p53 and bcl-2 proteins. 
It is generally believed that the tumor cells must achieve
resistance toward FasL-induced killing in order to escape a
cytotoxic attack by FasL-positive T cells (6). This selective
pressure has led them to either down-regulate or even lose
receptor expression. Resistance to Fas-mediated apoptosis
has been reported previously from several malignant tumors
including carcinomas of the colon (7), liver (19), and lung
(4, 9). The strong membranous expression of Fas receptor
could be readily demonstrated by immunoperoxidase stain-
ing using anti-Fas monoclonal antibody. In this immunohis-
tochemical study using TMA, the membranous Fas was mar-
kedly decreased in 66 cases (60%) of 110 NSCLCs. This study,
therefore, demonstrates that the loss of Fas expression might
be an important pathway of pulmonary carcinogenesis by
allowing lung tumors to escape from Fas-mediated apopto-
sis, that is, apoptotic resistance. The reduced Fas expression
was found more frequently in the advanced stage than in the
earlier stages. It also appeared to be significantly associated
with higher nodal status. The clinicopathologic significance
of Fas expression in NSCLCs has not been fully understood
yet. A few previous studies reported that a Fas/FasL ratio less
than 1 was more frequent in advanced stages III-IV than in
Fig. 6. A rare case of large cell carcinoma with bcl-2 overexpres-
sion reveals diffuse perinuclear immunoreactivity for the cytoplas-
mic bcl-2 protein (×400).
Fas 
expression
No. of
cases
p
value
p53 overexpression
Positive (%) Negative (%)
Negative 66 38 (58) 28 (42) 0.371
Positive 43* 21 (49) 22 (51)
Table 2. Correlation between Fas expression and p53 overex-
pression in non-small cell lung carcinomas
*, A case was lost in this analysis due to the failure in p53 immunostaining.
Fas 
expression
No. of
cases
p
value*
bcl-2 overexpression
Positive (%) Negative (%)
Negative 66 3 (5) 63 (95) 0.263
Positive 44 5 (11) 39 (89)
Table 3. Correlation between Fas expression and bcl-2 overex-
pression in non-small cell lung carcinomas
*, Fisher exact test.Fas and FasL Expressions in Non-small Cell Lung Carcinomas 775
limited stages I-II (7) and the Fas expression was correlated
with the nodal status (11). Although this study showed no
association between Fas expression and the clinicopathologic
parameters such as age, tumor extent (pT), histologic type
and grade, two well-known prognostic factors such as stage
and nodal status were significantly associated with Fas expres-
sion. The associations between the loss of Fas expression and
the advanced NSCLCs suggest that defects in the apoptotic
pathway represent a critical element in the progression of
the NSCLCs. Together, these data support a role for the loss
of Fas-mediated apoptosis during tumorigenesis and tumor
progression in NSCLCs.
The data for the influences of the Fas expression on the survi-
val of NSCLC patients have been limited and controversial.
Uramoto et al. and Koomagi and Volm showed the patients
with positive Fas staining survived for longer period than those
with negative staining (10, 20). However, Esposito et al.
reported no prognostic value of Fas expression on overall sur-
vival in NSCLC patients (11). Our result for the survival data
showed that the survival times of Fas-negative carcinomas
were significantly shorter than those of Fas-positive tumors.
This fact might indicate that the decreased Fas expression in
NSCLCs has a bad prognostic implication.
FasL, the ligand of Fas, has been reported to transmit the
apoptotic signal via Fas receptor and to be produced by tumors
of diverse histogenetic origins including the lung (4, 5, 7, 19,
21, 22). It has also been advocated that FasL-expressing tumor
cells might induce the killing of Fas-expressing normal tissue
cells including immune cells such as T lymphocytes (7, 23).
In lung carcinomas, especially NSCLCs, there are somewhat
contradictory opinions for the pattern of FasL expression.
Niehans et al. reported that virtually all tumors including
NSCLCs express functional FasL protein (5), whereas Viard-
Leveugle et al. demonstrated decreased FasL expression in
most NSCLCs (72%), compared with normal lung tissue (4).
In this study using the criteria of Viard-Leveugle et al., how-
ever, most NSCLCs (89%) showed increased FasL expression
in comparison to their normal counterparts. These contra-
dictory results could be explained by the use of different tech-
nological methodologies or interpretation criteria. Also, our
data for FasL protein suggest that NSCLC cells showing in-
creased FasL expression could counteract the immune system
by killing activated T cells that have been shown to express
Fas strongly.
p53 tumor suppressor gene is the most frequently identi-
fied genetic change in human neoplasms including lung car-
cinomas (24, 25) and known to regulate the Fas gene expres-
sion as its promoter gene (13). A few precedent works showed
that accumulation of mutations with p53 gene and within
Fas promoter region containing putative p53-binding site,
could progressively silence Fas expression in the development
of NSCLCs (18, 26). In this study, 59 (54%) of the 109 NS-
CLCs were positive for p53 overexpression which is thought
to be equivalent to p53 gene mutation (16), but there was
no correlation between negative Fas expression and p53 over-
expression. However, their functions are not simple in vivo
and thus results of further genetic studies must be combined
with the functional data.
The bcl-2 oncogene is a suppressor of apoptosis and over-
expression of bcl-2 oncogene has been reported to be an impor-
tant mechanism of apoptotic resistance in Fas-expressing malig-
nant cells (27). The only published data for bcl-2 in NSCLCs
(10) showed no correlation between the Fas and bcl-2 expres-
sions, although there had been a suggestion that the balance
between Fas and bcl-2 may play an important role in the in-
duction of apoptosis (28). In this study, only 8 (7%) of the
110 NSCLCs were positive for bcl-2 overexpression, and which
showed no relationship with the Fas expression. Taken together,
bcl-2 overexpression does not seem to play a role as a main
mechanism of apoptotic resistance in NSCLCs.
The large-scale immunohistochemical study was performed
using a high-throughput TMA, for which will facilitate the
screening of a large number of tumors with minimal outlay
in reagents. Concerns about tumor representation in the mic-
roarray need to be addressed, but Hoos et al. validated the
use of TMAs for immunophenotyping of malignant tumors
and showed an excellent concordance for staining of three
antibodies between TMAs with triplicate cores per tumor
and the full sections (29).
In conclusion, the reduced membranous Fas expression as
a mechanism of apoptotic resistance seems to serve a large part
of the pulmonary carcinogenesis, which might predict poor
survival and have a bad prognostic implication. Also, the rare
bcl-2 overexpression suggests that it is unlikely to be involved
as a mechanism for the apoptotic resistance in NSCLCs, whereas
the increased FasL expression is considered an important basis
for the immune evasion of the lung tumor cells. 
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